Agilent's fiscal fourth-quarter profit rose, helped by strong sales of bio-analysis products.
Agilent announced quarterly income was lower than expected. Amid slowing orders by semiconductor manufacturers in Asia, Agilent's third quarter net income fell 19% from the year ago quarter, to 45 cents a share. Although the company had forecasted lower earnings (46 to 50 cents a share) in May, it was unable to meet these lower estimates.
Agilent revised its earnings expectation for Q3 to $1.38 billion to $1.42 billion, instead of its prior outlook of about $1.36 billion to $1.40 billion.
Earnings came in on 05/14/07 higher than expected, driven by growth in the bioanalytic segment
Agilent predicted earnings for the second quarter of 2007 that were higher than analysts' estimates.